Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis

Infection and Immunity

Volumn 66, Issue 6, 1998, Pages 2951-2959

  Baldwin, Susan L ^a   D'Souza, Celine ^a   Roberts, Alan D ^a   Kelly, Brian P ^a   Frank, Anthony A ^a   Lui, Margaret A ^b   Ulmer, Jeffrey B ^b   Huygen, Kris ^c   McMurray, David M ^d   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GUINEA PIG; IMMUNOREACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUBERCULOSIS; VACCINATION; VACCINE PRODUCTION;

EID: 0031841258     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.6.2951-2959.1998     Document Type: Article

References (29)

1. Afonso, L. C. C., T. M. Scharton, L. Z. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994, The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235-237.
2. Andersen, P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:2536-2544.
3. Belisle, J. T., V. D. Vissa, T. Sievert, K. Takayama, P. J. Brennan, and G. S. Besra. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420-1422.
4. Bloom, B. R., and P. E. M. Fine. 1994. The BCG experience: implications for future vaccines against tuberculosis, p. 531-557. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
5. Castro, A. G., R. A. Silva, and R. Appelberg. 1995. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections. J. Immunol. 155:2013-2019.
6. Cooper, A. M., A. D. Roberts, E. R. Rhoades, J. E. Callahan, D. M. Getzy, and I. M. Orme. 1995. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 84:423-432.
7. Flynn, J. L., M. M. Goldstein, K. J. Triebold, J. Sypek, S. Wolf, and B. R. Bloom. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515-2524.
8. Fries, L. F., D. M. Gordon, R. L. Richards, J. E. Egan, M. R. Hollingdale, M. Gross, C. Silverman, and C. R. Alving. 1992. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 89:358-362.
9. Horwitz, M. A., B.-W. E. Lee, B. J. Dillon, and G. H. Harth. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 92: 1530-1534.
10. Hubbard, R. D., C. M. Flory, and F. M. Collins. 1992. Immunization of mice with mycobacterial culture filrate proteins. Clin. Exp. Immunol. 87:94-98.
11. Huygen, K., J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, R. R. Deck, C. DeWitt, I. M. Orme, S. Baldwin, C. D'Souza, A. Drowart, E. Lozes, P. Vandenbussche, J.-P. Van Vooren, M. A. Liu, and J. B. Ulmer. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2:893-898.
12. Koutsoukos, M., G. Leroux, P. Vandepapeliere, M. Slaoui, and P. Pala. 1994. Induction of cell mediated immune responses in man with vaccines against herpes simplex virus based on glycoprotein D, p. 217. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. McMurray, D. N. 1994. Guinea pig model of tuberculosis, p. 113-134. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
14. Mitchell, M. S., W. Harel, R. A. Kempf, E. Hu, J. Kan-Mitchell, W. D. Boswell, G. Dean, and L. Stevenson. 1990. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48:5883-5893.
15. Mountford, A. P., S. Anderson, and R. A. Wilson. 1996. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J. Immunol. 156:4739-4745.
16. Orme, I. M. 1988. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance, in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 56:3310-3312.
17. Orme, I. M. 1997. Progress in the development of new vaccines against tuberculosis. Int. J. Tuberc. Lung Dis. 1:95-100.
18. Orme, I. M. 1995. Prospects for new vaccines against tuberculosis. Trends Microbiol. 3:401-404.
19. Orme, I. M., P. Andersen, and W. H. Boom. 1993. T cell response to Mycobacterium tuberculosis. J. Infect. Dis. 167:1481-1497.
20. Pal, P. G., and M. A. Horwitz. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:4781-4792.
21. Raviglione, M. C., D. E. Snider, and A. Kochi. 1995. Global epidemiology of tuberculosis. JAMA 273:220-226.
22. Roberts, A. D., M. J. Sonnenberg, D. J. Ordway, S. K. Furney, P. J. Brennan, J. T. Belisle, and I. M. Orme. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85:502-508.
23. Roche, P. W., J. A. Triccas, and N. Winter. 1995. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol. 3:397-401.
24. Rodrigues, L., and P. G. Smith. 1990. Tuberculosis in developing countries and methods for its control. Trans. R. Soc. Trop. Med. Hyg. 84:739-744.
25. Rudbach, J. A., D. A. Johnson, and J. T. Ulrich. 1995. RIBI adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine, p. 287-313. In D. E. S. Stewart-Tull (ed.), The theory and practical application of adjuvants. John Wiley & Sons, Inc., New York. N.Y.
26. Saunders, B. M., Y. Zhan, and C. Cheers. 1995. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect. Immun. 63:4011-4015.
27. Sypek, J. P., C. L. Chung, S. E. H. Mayor, J. M. Subramanyam, S. L. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797-1802.
28. Teppler, H., G. Kaplan, K. A. Smith, A. L. Montana, P. Meyn, and Z. A. Cohn. 1993. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. 177:483-492.
29. World Health Organization. 1979. Trial of BCG vaccines in South India for tuberculosis prevention. Bull. W. H. O. 57:810-827.